Zoetis (NYSE:ZTS) Announces Earnings Results, Beats Estimates By $0.08 EPS

Zoetis (NYSE:ZTS) announced its quarterly earnings data on Tuesday. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08, Zacks reports. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. During the same period in the previous year, the firm posted $1.38 earnings per share. Zoetis’s revenue was up 1.4% compared to the same quarter last year. Zoetis updated its FY 2025 guidance to 6.200-6.30 EPS.

Zoetis Price Performance

Shares of Zoetis stock traded down $5.72 during trading hours on Tuesday, hitting $152.34. The company’s stock had a trading volume of 1,312,088 shares, compared to its average volume of 2,466,192. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis has a 12-month low of $139.70 and a 12-month high of $200.33. The business has a 50 day moving average price of $158.17 and a two-hundred day moving average price of $166.80. The company has a market cap of $67.97 billion, a PE ratio of 27.88, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.31%. Zoetis’s payout ratio is 36.56%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Piper Sandler upped their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Stifel Nicolaus decreased their price target on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. Barclays lifted their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $214.40.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is owned by insiders.

Hedge Funds Weigh In On Zoetis

An institutional investor recently raised its position in Zoetis stock. Brighton Jones LLC lifted its position in Zoetis Inc. (NYSE:ZTS) by 180.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,629 shares of the company’s stock after acquiring an additional 2,978 shares during the quarter. Brighton Jones LLC’s holdings in Zoetis were worth $754,000 at the end of the most recent reporting period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.